Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...
The Swiss National Bank must have the ability to take interest rates below zero to efficiently control the strength of the ...
U.S. District Judge Analisa Torres allowed investors to proceed as a class on the price manipulation claims, turning aside ...
Swiss Life is buying asset manager Zwei Wealth to expand its investment business for high net worth individuals and institutional clients. The Swiss life insurer said Wednesday said the parties agreed ...
Swiss food giant Nestle reported better-than-expected annual sales on Thursday, boosting its shares after the maker of ...
Strong appetite for sub-benchmark pair â—† Julius Baer issues in dollars after no replacement of Swiss franc AT1 last year â—† ...
The Swiss franc could extend its recent decline if optimism over a Ukraine-Russia ceasefire deal reduces safe-haven demand and data Thursday show Swiss inflation eased in January, ING said.
SGS shares rose after profitability last year beat analysts' expectations, and the company guided for further improvements in 2025. Shares in the Swiss testing, inspection and certification company ...
New deal marks the first broadly wholesale capital issuance in Swiss francs after Credit Suisse's demise, say local bankers ...
The Switzerland market closed weak on Friday after a choppy session, as investors stayed a bit reluctant to make significant moves ...
The Swiss franc could appreciate in coming months as the Swiss National Bank is unlikely to return to negative interest rates, Commerzbank analyst Michael Pfister says in a note.
Givaudan's fiscal year 2024 results were strong despite currency headwinds. Click here to see why GVDBF stock is a Hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback